![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
Sponsors and Collaborators: |
National Center for Research Resources (NCRR) University of Michigan |
---|---|
Information provided by: | Office of Rare Diseases (ORD) |
ClinicalTrials.gov Identifier: | NCT00004643 |
OBJECTIVES: I. Evaluate the toxicity of cytarabine in patients with refractory systemic lupus erythematosus.
II. Evaluate objective disease parameters, including serum complement levels, anti-DNA antibody titers, sedimentation rate, and the systemic lupus activity measure in these patients.
Condition | Intervention | Phase |
---|---|---|
Lupus Erythematosus, Systemic |
Drug: cytarabine |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Open Label |
Ages Eligible for Study: | 18 Years to 64 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
PROTOCOL ENTRY CRITERIA:
Disease Characteristics
Prior/Concurrent Therapy
Patient Characteristics
Study ID Numbers: | 199/11685, UMMC-91208 |
Study First Received: | February 24, 2000 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00004643 History of Changes |
Health Authority: | United States: Federal Government |
arthritis & connective tissue diseases immunologic disorders and infectious disorders rare disease systemic lupus erythematosus |
Antimetabolites Anti-Infective Agents Autoimmune Diseases Immunologic Factors Lupus Erythematosus, Systemic Lupus |
Arthritis Rare Diseases Connective Tissue Diseases Immunosuppressive Agents Antiviral Agents Cytarabine |
Antimetabolites Anti-Infective Agents Autoimmune Diseases Antimetabolites, Antineoplastic Immunologic Factors Immune System Diseases Molecular Mechanisms of Pharmacological Action Antineoplastic Agents |
Physiological Effects of Drugs Immunosuppressive Agents Antiviral Agents Pharmacologic Actions Lupus Erythematosus, Systemic Therapeutic Uses Connective Tissue Diseases Cytarabine |